CD4 and hepatitis B virus infection: Thus the significant change in the CD4 T count recorded among the study participants prior to TLE/ZLE administration within 5 months was independent of age, gender, comorbidities (TB and hepatitis B infections), and baseline CD4 and CD8 cell counts.